Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157
Tel: +81 (0)80-1164-4754
Request a Demo
What our customers are saying
When I think of the future, I think of EvaluatePharma
Global pharmaceutical company
EP Vantage Pharma & Biotech 2016 in Review
The annual EP Vantage Pharma & Biotech 2016 in Review report offers analysis and expert commentary on M&A deals venture financing, initial public offerings and FDA approvals in the pharma and biotech sector during 2016.
For the world’s drug makers 2016 was a year of two halves. Activity like deal-making and venture funding held up over the first two quarters, buoyed by the retreating bull market. However, as the US presidential election loomed ever closer, companies went into lockdown.
Key findings include:
- The Nasdaq Biotechnology Index ended in the red for the first time since 2008
- The $98.7bn spent on pharma & biotech acquisitions in 2016 was less than half that of the biotech boom’s peak in 2014
- The fourth quarter saw three venture rounds breaking the $200m barrier; with Moderna Therapeutics exceeding $1bn
EP Vantage is an independent editorial team providing daily commentary and analysis that allows our readers to quickly understand what is important and why. Our high quality, data-driven analysis is trusted, insightful and thought provoking, enabling our readers to make informed decisions.
EP Vantage Medtech 2016 in Review
Confirm your details on form below to download this report